Cargando…

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

Inactivating PTEN mutations are commonly found in prostate cancer, resulting in an increased activation of Akt. In this study, we investigate the role of PTEN deletion and protein expression in the development of hormone-refractory prostate cancer using matched hormone-sensitive and hormone-refracto...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCall, P, Witton, C J, Grimsley, S, Nielsen, K V, Edwards, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570524/ https://www.ncbi.nlm.nih.gov/pubmed/18854827 http://dx.doi.org/10.1038/sj.bjc.6604680

Ejemplares similares

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
por: Yoshimoto, M, et al.
Publicado: (2007)

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
por: Willder, J M, et al.
Publicado: (2013)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma
por: Beg, S, et al.
Publicado: (2015)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
por: Attard, G, et al.
Publicado: (2008)

Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression
por: Elsberger, B, et al.
Publicado: (2010)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells
por: Watanabe, T, et al.
Publicado: (2011)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Slow proliferation as a biological feature of colorectal cancer metastasis
por: Anjomshoaa, A, et al.
Publicado: (2009)

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement
por: Foster, C S, et al.
Publicado: (2009)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer
por: Kachroo, N, et al.
Publicado: (2013)

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
por: Avgeris, M, et al.
Publicado: (2013)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
por: Domingo-Domenech, J, et al.
Publicado: (2005)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein
por: McClurg, Urszula L, et al.
Publicado: (2018)

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
por: Elkahwaji, J E, et al.
Publicado: (2009)

Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
por: Gowardhan, B, et al.
Publicado: (2005)

Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients
por: Le Page, C, et al.
Publicado: (2006)

The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer
por: Gujam, F J A, et al.
Publicado: (2014)

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients
por: Hagman, Z, et al.
Publicado: (2013)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
por: Clarke, C L, et al.
Publicado: (2006)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer
por: Mohammed, Z M A, et al.
Publicado: (2012)

Study of matrix metalloproteinases and their inhibitors in prostate cancer
por: Escaff, S, et al.
Publicado: (2010)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9qaqhpd8t215ctgn5h1sc8tqan